245 related articles for article (PubMed ID: 23178313)
1. Preoperative HE4 expression in plasma predicts surgical outcome in primary ovarian cancer patients: results from the OVCAD study.
Braicu EI; Fotopoulou C; Van Gorp T; Richter R; Chekerov R; Hall C; Butz H; Castillo-Tong DC; Mahner S; Zeillinger R; Concin N; Vergote I; Sehouli J
Gynecol Oncol; 2013 Feb; 128(2):245-51. PubMed ID: 23178313
[TBL] [Abstract][Full Text] [Related]
2. Postoperative human epididymis protein 4 predicts primary therapy outcome in advanced epithelial ovarian cancer.
Vallius T; Hynninen J; Auranen A; Matomäki J; Oksa S; Roering P; Grènman S
Tumour Biol; 2017 Feb; 39(2):1010428317691189. PubMed ID: 28218038
[TBL] [Abstract][Full Text] [Related]
3. The role of HE4 for prediction of recurrence in epithelial ovarian cancer patients-results from the OVCAD study.
Nassir M; Guan J; Luketina H; Siepmann T; Rohr I; Richter R; Castillo-Tong DC; Zeillinger R; Vergote I; Van Nieuwenhuysen E; Concin N; Marth C; Hall C; Mahner S; Woelber L; Sehouli J; Braicu EI
Tumour Biol; 2016 Mar; 37(3):3009-16. PubMed ID: 26419591
[TBL] [Abstract][Full Text] [Related]
4. Preoperative serum CA125 levels do not predict suboptimal cytoreductive surgery in epithelial ovarian cancer.
Arits AH; Stoot JE; Botterweck AA; Roumen FJ; Voogd AC
Int J Gynecol Cancer; 2008; 18(4):621-8. PubMed ID: 17868339
[TBL] [Abstract][Full Text] [Related]
5. A novel index for preoperative, non-invasive prediction of macro-radical primary surgery in patients with stage IIIC-IV ovarian cancer-a part of the Danish prospective pelvic mass study.
Karlsen MA; Fagö-Olsen C; Høgdall E; Schnack TH; Christensen IJ; Nedergaard L; Lundvall L; Lydolph MC; Engelholm SA; Høgdall C
Tumour Biol; 2016 Sep; 37(9):12619-12626. PubMed ID: 27440204
[TBL] [Abstract][Full Text] [Related]
6. Serum HE4 superior to CA125 in predicting poorer surgical outcome of epithelial ovarian cancer.
Shen Y; Li L
Tumour Biol; 2016 Nov; 37(11):14765-14772. PubMed ID: 27629144
[TBL] [Abstract][Full Text] [Related]
7. The Role of HE4, a Novel Biomarker, in Predicting Optimal Cytoreduction After Neoadjuvant Chemotherapy in Advanced Ovarian Cancer.
Plotti F; Scaletta G; Capriglione S; Montera R; Luvero D; Lopez S; Gatti A; De Cicco Nardone C; Terranova C; Angioli R
Int J Gynecol Cancer; 2017 May; 27(4):696-702. PubMed ID: 28406844
[TBL] [Abstract][Full Text] [Related]
8. HE4, CA125 and risk of ovarian malignancy algorithm (ROMA) as diagnostic tools for ovarian cancer in patients with a pelvic mass: An Italian multicenter study.
Romagnolo C; Leon AE; Fabricio ASC; Taborelli M; Polesel J; Del Pup L; Steffan A; Cervo S; Ravaggi A; Zanotti L; Bandiera E; Odicino FE; Scattolo N; Squarcina E; Papadakis C; Maggino T; Gion M
Gynecol Oncol; 2016 May; 141(2):303-311. PubMed ID: 26801941
[TBL] [Abstract][Full Text] [Related]
9. HE4 expression in plasma correlates with surgical outcome and overall survival in patients with first ovarian cancer relapse.
Braicu EI; Chekerov R; Richter R; Pop C; Nassir M; Loefgren H; Stamatian F; Muallem MZ; Hall C; Fotopoulou C; Sehouli J; Pietzner K
Ann Surg Oncol; 2014 Mar; 21(3):955-62. PubMed ID: 24217786
[TBL] [Abstract][Full Text] [Related]
10. Serum HE4 and CA125 as predictors of response and outcome during neoadjuvant chemotherapy of advanced high-grade serous ovarian cancer.
Vallius T; Hynninen J; Auranen A; Carpén O; Matomäki J; Oksa S; Virtanen J; Grénman S
Tumour Biol; 2014 Dec; 35(12):12389-95. PubMed ID: 25190018
[TBL] [Abstract][Full Text] [Related]
11. Comparison of HE4, CA125 and ROMA algorithm in women with a pelvic mass: correlation with pathological outcome.
Sandri MT; Bottari F; Franchi D; Boveri S; Candiani M; Ronzoni S; Peiretti M; Radice D; Passerini R; Sideri M
Gynecol Oncol; 2013 Feb; 128(2):233-8. PubMed ID: 23200911
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of human epididymis protein 4 in epithelial ovarian cancer.
Paek J; Lee SH; Yim GW; Lee M; Kim YJ; Nam EJ; Kim SW; Kim YT
Eur J Obstet Gynecol Reprod Biol; 2011 Oct; 158(2):338-42. PubMed ID: 21683503
[TBL] [Abstract][Full Text] [Related]
13. Outcome and clinical management of 275 patients with advanced ovarian cancer International Federation of Obstetrics and Gynecology II to IV inside the European Ovarian Cancer Translational Research Consortium-OVCAD.
Chekerov R; Braicu I; Castillo-Tong DC; Richter R; Cadron I; Mahner S; Woelber L; Marth C; Van Gorp T; Speiser P; Zeillinger R; Vergote I; Sehouli J
Int J Gynecol Cancer; 2013 Feb; 23(2):268-75. PubMed ID: 23358178
[TBL] [Abstract][Full Text] [Related]
14. HE4, CA125, the Risk of Malignancy Algorithm and the Risk of Malignancy Index and complex pelvic masses - a prospective comparison in the pre-operative evaluation of pelvic masses in an Australian population.
Richards A; Herbst U; Manalang J; Pather S; Saidi S; Tejada-Berges T; Tan K; Williams P; Carter J
Aust N Z J Obstet Gynaecol; 2015 Oct; 55(5):493-7. PubMed ID: 26172511
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic performance of the biomarkers HE4 and CA125 in type I and type II epithelial ovarian cancer.
Kristjansdottir B; Levan K; Partheen K; Sundfeldt K
Gynecol Oncol; 2013 Oct; 131(1):52-8. PubMed ID: 23891789
[TBL] [Abstract][Full Text] [Related]
16. A Predictive Score for Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer (SeC-Score): A Single-Centre, Controlled Study for Preoperative Patient Selection.
Angioli R; Capriglione S; Aloisi A; Ricciardi R; Scaletta G; Lopez S; Miranda A; Di Pinto A; Terranova C; Plotti F
Ann Surg Oncol; 2015 Dec; 22(13):4217-23. PubMed ID: 25808099
[TBL] [Abstract][Full Text] [Related]
17. Preoperative serum levels of HE4 and CA125 predict primary optimal cytoreduction in advanced epithelial ovarian cancer: a preliminary model study.
Feng LY; Liao SB; Li L
J Ovarian Res; 2020 Feb; 13(1):17. PubMed ID: 32050995
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of residual tumor size in patients with epithelial ovarian cancer FIGO stages IIA-IV: analysis of the OVCAD data.
Polterauer S; Vergote I; Concin N; Braicu I; Chekerov R; Mahner S; Woelber L; Cadron I; Van Gorp T; Zeillinger R; Castillo-Tong DC; Sehouli J
Int J Gynecol Cancer; 2012 Mar; 22(3):380-5. PubMed ID: 22266934
[TBL] [Abstract][Full Text] [Related]
19. Correlation of preoperative ROMA scores with clinical stage in epithelial ovarian cancer patients.
Li QL; Wang CJ; Qi P; Zhang YX
Clin Transl Oncol; 2017 Oct; 19(10):1260-1267. PubMed ID: 28444641
[TBL] [Abstract][Full Text] [Related]
20. Prognostic impact of debulking surgery and residual tumor in patients with epithelial ovarian cancer FIGO stage IV.
Ataseven B; Grimm C; Harter P; Heitz F; Traut A; Prader S; du Bois A
Gynecol Oncol; 2016 Feb; 140(2):215-20. PubMed ID: 26691222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]